Influence of different recombinant systems on the cooperativity exhibited by cytochrome P4503A4

Xenobiotica

Volumn 34, Issue 5, 2004, Pages 473-486

  Zhang, Z ^a   Li, Y ^a   Shou, M ^a   Zhang, Y ^a   Ngui, J S ^a   Stearns, R A ^a   Evans, D C ^a   Baillie, T A ^a   Tang, W ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUFFER; CYTOCHROME P450 3A4; DETERGENT; DICLOFENAC; PIROXICAM; QUINIDINE; RECOMBINANT ENZYME; WARFARIN;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; COOPERATION; CULTURE MEDIUM; DRUG HYDROXYLATION; DRUG METABOLISM; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; INSECT CELL; ISOMER; LIVER MICROSOME; LYMPHOBLAST; METABOLIC RATE; NONHUMAN; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; SOLUBILIZATION;

ANIMALS; CELL LINE; CYTOCHROME P-450 ENZYME SYSTEM; DICLOFENAC; DRUG INTERACTIONS; HUMANS; HYDROXYLATION; KINETICS; MICROSOMES, LIVER; MODELS, BIOLOGICAL; PIROXICAM; QUINIDINE; RECOMBINANT PROTEINS; WARFARIN;

ANIMALIA; INSECTA;

EID: 3142514405     PISSN: 00498254     EISSN: None     Source Type: Journal    
DOI: 10.1080/00498250410001691271     Document Type: Article

References (37)

1. ATKINS, W. M., WANG, R. and Lu, A. Y.-H., 2001, Allosteric behavior in cytochrome P450-dependent in vitro drug-drug interactions: a prospective based on conformational dynamics. Chemical Research in Toxicology, 14, 338-347.
2. BUENING, M. K., CHANG, R. L., HUANG, M.-T., FORTNER, J. G., WOOD, A. W. and CONNEY, A. H., 1981, Activation and inhibition of benzo(a)pyrene and aflatoxin B1 metabolism in human liver microsomes by naturally occurring flavonoids. Cancer Research, 41, 67-72.
3. CRESPI, C. and MILLER, V., 1999, The use of heterologously expressed drug metabolizing enzymes - state of the art and prospects for the future. Pharmacology and Therapeutics, 84, 121-131.
4. DOMANSKI, T. L., HE, Y. A., HARLOW, G. R. and HALPERT, J. R., 2000, Dual role of human cytochrome P450 3A4 residue Phe-304 in substrate specificity and cooperativity. Journal of Pharmacology and Experimental Therapeutics, 293, 585-591.
5. EGNELL, A.-C., HOUSTON, B. and BOYER, S., 2003, In vivo CYP3A4 heteroactivation is a possible mechanism for the drug interaction between felbamate and carbamazepine. Journal of Pharmacology and Experimental Therapeutics, 305, 1251-1262.
6. EMOTO, C., YAMAZAKI, H., IKETAKI, H., YAMASAKI, S., SATOH, T., SHIMIZU, R., SUZUKI, S., SHIMADA, N., NAKAJIMA, M. and YOKOI, T., 2001, Cooperativity of α-naphthoflavone in cytochrome P450 3A-dependent drug oxidation activities in hepatic and intestinal microsomes from mouse and human. Xenobiotica, 31, 265-275.
7. GALETIN, A., CLARKE, S. E. and HOUSTON, J. B., 2002, Quinidine and haloperidol as modifiers of CYP3A4 activity: multisite kinetic model approach. Drug Metabolism and Disposition, 30, 1512-1522.
8. GONZALEZ, F. J. and KORZEKWA, K. R., 1995, Cytochrome P450 expression systems. Annual Review in Pharmacology and Toxicology, 35, 369-390.
9. GUENGERICH, F. P., 1997, Role of cytochrome P450 enzymes in drug-drug interactions. Advances in Pharmacology, 43, 7-35.
10. HARLOW, G. R. and HALPERT, J. R., 1998, Analysis of human cytochrome P450 3A4 cooperativity: construction and characterization of a site-directed mutant that displays hyperbolic steroid hydroxylation kinetics. Proceedings of the National Academy of Sciences, USA, 95, 6636-6641.
11. HOSEA, N. A., MILLER, G. P. and GUENGERICH, F. P., 2000, Elucidation of distinct ligand binding sites for cytochrome P450 3A4. Biochemistry, 39, 5929-5939.
12. HUTZLER, J. M., HAUER, M. J. and TRACY, T. S., 2001, Dapsone activation of CYP2C9-mediated metabolism: evidence for activation of multiple substrates and a two-site model. Drug Metabolism and Disposition, 29, 1029-1034.
13. INGELMAN-SUNDBERG, M., 1986, Cytochrome P-450 organization and membrane interactions. In P. R. Ortiz de Montellano (ed.), Cytochrome P450. Structure, Mechanism, and Biochemistry (New York: Plenum), pp. 119-160.
14. JOHNSON, E. F., 2003, Deciphering substrate recognition by drug-metabolizing cytochrome P450. Drug Metabolism and Disposition, 31, 1532-1540.
15. KERR, B. M., THUMMEL, K. E., WURDEN, C. J., KLEIN, S. M., KROETZ, D. L., GONZALEZ, F. J. and LEVY, R. H., 1994, Human liver carbamazepine metabolism. Role of CYP3A4 and CYP2C8 in 10,11-epoxide formation. Biochemical Pharmacology, 47, 1969-1979.
16. KOLEY, A. P., BUTERS, J. T. M., ROBINSON, R. C., MARKOWITZ, A. and FRIEDMAN, F. K., 1997, Differential mechanism of cytochrome P450 inhibition and activation by α-naphtheflavone. Journal of Biological Chemistry, 272, 3149-3152.
17. KORZEKWA, K. R., KRISHNAMACHARY, N., SHOU, M., OGAI, A., PARISE, R. A., RETTIE, A. E., GONZALEZ, F. J. and TRACY, T. S., 1998, Evaluation of atypical cytochrome P450 kinetics with two-substrate models: evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites. Biochemistry, 37, 4137-4147.
18. LE MAIRE, M., CHAMPEIL, P. and MOLLER, J. V., 2000, Interaction of membrane proteins and lipids with solubilizing detergents. Biochimica et Biophysica Acta, 1508, 86-111.
19. LOMBARDINO, J. G., 1981, Synthesis and antiinflammatory activity of metabolites of piroxicam. Journal of Medicinal Chemistry, 24, 39-42.
20. LUDWIG, E., SCHMID, J., BESCHKE, K. and EBNER, T., 1999, Activation of human cytochrome P-450 3A4-catalysed meloxicam 5′-methylhydroxylation by quinidine and hydroquinidine in vitro. Journal of Pharmacology and Experimental Therapeutics, 290, 1-8.
21. MARQUARDT, D. W., 1963, An algorithm for least-squares estimation of nonlinear parameters. Journal of the Society of Industrial and Applied Mathematics, 11, 431-441.
22. NEWTON, D. J., WANG, R. W. and Lu, A. Y.-H., 1995, Cytochrome P450 inhibitors: Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metabolism and Disposition, 23, 154-158.
23. NGUI, J. S., CHEN, Q., SHOU, M., WANG, R., STEARNS, R. A., BAILLIE, T. A. and TANG, W., 2001, In vitro stimulation of warfarin metabolism by quinidine: Increases in the formation of 4′- and 10-hydroxywarfarin. Drug Metabolism and Disposition, 29, 877-886.
24. NGUI, J. S., TANG, W., STEARNS, R. A., SHOU, M., MILLER, R. R., ZHANG, Y., LIN, J. H. and BAILLIE, T. A., 2000, Cytochrome P450 3A4-mediated interactions of diclofenac and quinidine. Drug Metabolism and Disposition, 28, 1043-1050.
25. NIWA, T., SHIRAGA, T., YAMASAKI, S., ISHIBASHI, K., OHNO, Y. and KAGAYAMA, A., 2003, In vitro activation of 7-benzyloxyresorufin O-debenzylation and nifedipine oxidation in human liver microsomes. Xenobiotica, 7, 717-729.
26. OMURA, T. and SATO, R. 1964, The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. Journal of Biological Chemistry, 239, 2370-2378.
27. RAUCY, J. L. and LASKER, J. M., 1991, Isolation of P450 enzymes from human liver. Methods in Enzymology, 206, 557-587.
28. SHOU, M., MEI, Q., ETTORE, M. W., JR, DAI, R., BAILLIE, T. A. and RUSHMORE, T. H., 1999, Sigmoidal kinetic model for two cooperative substrate-binding sites in a cytochrome P450 3A4 active site: an example for the metabolism of diazepam and its derivatives. Biochemical Journal, 340, 845-853.
29. TANG, W., STEARNS, R. A., BANDIERA, S. M., ZHANG, Y., RAAB, C., BRAUN, M. P., DEAN, D. C., PANG, J., LEUNG, K. H., Doss, G. A., STRAUSS, J. R., KWEI, G. Y., RUSHMORE, T. H., CHIU, S.-H. L. and BAILLIE, T. A., 1999b, Studies on hepatic cytochrome P450-mediated bioactivation of diclofenac in rats and in human hepatocytes: identification of glutathione conjugated metabolites. Drug Metabolism and Disposition, 27, 365-372.
30. TANG, W., STEARNS, R. A., KWEI, G. Y., ILIFF, S. A., MILLER, R. R., EGAN, M. A., YU, N. X., DEAN, D. C., KUMAR, S., SHOU, M., LIN, J. H. and BAILLIE, T. A., 1999a, Interaction of diclofenac and quinidine in monkeys: stimulation of diclofenac metabolism. Journal of Pharmacology and Experimental Therapeutics, 291, 1068-1074.
31. TANG, W. and STEARNS, R. A., 2001, Heterotropic cooperativity in cytochrome P4503A4 and potential drug-drug interactions. Current Drug Metabolism, 2, 185-198.
32. UENG, Y.-F., KUWABARA, T., CHUN, Y.-J. and GUENGERICH, F. P., 1997, Cooperativity in oxidations catalysed by cytochrome P450 3A4. Biochemistry, 36, 370-381.
33. WANG, R. W., NEWTON, D. J., LIU, N., ATKINS, W. M. and LU, A. Y.-H., 2000, Human cytochrome P-450 3A4: in vitro drug-drug interaction patterns are substrate-dependent. Drug Metabolism and Disposition, 28, 360-366.
34. WILLIAMS, P. A., COSME, J., WARD, A., ANGOVE, H. C., VINKOVIC, D. M. and JHOTI, H., 2003, Crystal structure of human cytochrome P450 2C9 with bound warfarin. Nature, 424, 464-468.
35. WRIGHTON, S. A. and STEVENS, J. C., 1992, The human hepatic cytochrome P450 involved in drug metabolism. Critical Reviews in Toxicology, 22, 1-21.
36. XUE, J., WANG, H. F., WANG, Q., SZKLARZ, G. D., DOMANSKI, T. L., HALPERT, J. R. and CORREIA, M. A., 2001, Influence of P450 3A4 SRS-2 residues on cooperativity and/or regioselectivity of aflatoxin B1 oxidation. Chemical Research in Toxicology, 14, 483-491.
37. ZHAO, J., LEEMANN, T. and DAYER, P., 1992, In vitro oxidation of oxicam NSAIDS by a human liver cytochrome P450. Life Sciences, 51, 575-581.